Waters stock coverage resumed at Evercore ISI with In Line rating
#Waters Corporation #Evercore ISI #Stock Rating #Equity Research #Investment Analysis #Life Sciences Market #Price Target
📌 Key Takeaways
- Evercore ISI has officially resumed investment coverage of Waters Corporation.
- The stock was assigned an 'In Line' rating, indicating a neutral performance expectation.
- A price target of $370 per share has been established by the analysts.
- The analytical instrument sector is currently facing complex market conditions and cautious spending.
📖 Full Retelling
Evercore ISI financial analysts officially resumed coverage of Waters Corporation (WAT) on the New York Stock Exchange this week, assigning the specialty measurement company an 'In Line' rating and a price target of $370. This decision marks a neutral stance by the investment firm, reflecting a balanced view of the company's valuation and growth prospects within the current macroeconomic environment. The move to restart coverage allows investors to gain renewed insights into the company’s performance as the analytical instrument sector faces shifting demand patterns.
The 'In Line' designation suggests that Evercore ISI expects Waters Corporation to perform roughly in accordance with the average return of the other stocks in the analysts' coverage universe. Analysts noted that while the company maintains a strong position in the high-end liquid chromatography and mass spectrometry markets, the broader life sciences industry has been navigating a period of cautious capital expenditure. This professional assessment serves as a benchmark for institutional investors who rely on Evercore's research to calibrate their portfolios against sector-specific volatility.
Waters Corporation, headquartered in Milford, Massachusetts, serves as a critical provider for the pharmaceutical, biochemical, and industrial markets. The resumption of coverage by a major firm like Evercore ISI often signals a period of relative stability or a significant point of evaluation for a stock. At the current price target of $370, the financial analysts are signaling that the company is fairly valued based on its projected earnings and operational efficiency, despite the competitive pressures found in the global laboratory equipment market.
🏷️ Themes
Finance, Economy, Stock Market
📚 Related People & Topics
Waters Corporation
American instrument company
Waters Corporation, headquartered in Milford, Massachusetts, provides analytical instruments and software used for chromatography, mass spectrometry, laboratory informatics, and rheometry by the life, materials and food sciences industries. The company has primary manufacturing facilities in 9 U.S. ...
Evercore
American financial services company
Evercore Inc., formerly known as Evercore Partners, is a global independent investment banking advisory firm founded in 1995 by Roger Altman, David Offensend, and Austin Beutner. The firm has advised on over $4.7 trillion of merger, acquisition, and restructuring transactions since its founding. Eve...
🔗 Entity Intersection Graph
Connections for Waters Corporation:
- 🏢 TD Cowen (1 shared articles)
📄 Original Source Content
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry As Claude disrupts stock market, Anthropic researcher warns ’world is in peril’ Gold, silver prices rise amid U.S.-Iran tensions, blowout January payrolls data Dow halts three-day win streak as blowout jobs data curbs rate cut bets Citi pushes back Fed rate cuts to May after blowout January jobs report (South Africa Philippines Nigeria) Waters stock coverage resumed at Evercore ISI with In Line rating Analyst Ratings Published 02/09/2026, 04:55 PM Waters stock coverage resumed at Evercore ISI with In Line rating 0 WAT 0.69% Investing.com - Evercore ISI analyst has resumed coverage on Waters Corp. (NYSE:WAT) with an In Line rating and a price target of $360.00. This target aligns closely with InvestingPro ’s Fair Value assessment, which suggests the stock is slightly undervalued at its current price of $328.14. The research firm’s decision comes as Waters shares have declined 13% recently due to three key factors identified in the analyst note. Despite this recent drop, Waters still maintains a 35.6% price return over the past six months. The first concern involves the BD Life Sciences business, which declined 10% in the December quarter, raising questions about fiscal year 2026 growth assumptions for the newly combined entity. Additional factors weighing on the stock include earnings being weighted toward the second half of the year and operating margins that missed expectations in the fourth quarter, with earnings per share supported by lower taxes. Evercore ISI’s $360 price target represents approximately 25 times calendar year 2026 price-to-earnings ratio and about 21 times EBITDA, with the firm’s fiscal year 2026 EPS estimate set at $14.36, falling in the lower half of the projected range. For deeper analysis, InvestingPro offers a comprehensive Research Report on Waters Corp, part of its coverage of 1,400+ US equities. In other recent news, Waters Corporation reported its fourth-quarter 2025 earnings, sl...